Stratification of the cohort into patients with (n = 104) and without (n = 234) KRAS mutation found that a high TAM density was associated with poor survival in KRAS mutant CRC cases (CD163+ cells: log-rank test: p = 0.003; hazard ratio, 3.63; 95% CI, [1.44–9.16]; CD206+ cells: log-rank test, p = 0.005; hazard ratio, 3.31; 95% CI, [1.37–8.01]), but not in cases with wild-type KRAS (log-rank test: p > 0.05) (Fig. 1c, d). This evidence concerns the gene CD163 and colorectal carcinoma.